GLP-1 Weight Loss Injections — What Florida Patients Should Know

If you've been paying attention to weight loss news over the past two years, you've probably heard of GLP-1 medications. Names like Ozempic, Wegovy, Mounjaro, and Zepbound have gone from medical conferences to dinner table conversations. And for good reason — these medications represent a genuine shift in how physicians approach weight management.

But between the celebrity endorsements, the shortage headlines, and the online noise, it can be hard to separate what's real from what's hype. Here's what you actually need to know as a Florida patient considering GLP-1 therapy.

What Are GLP-1 Medications?

GLP-1 stands for glucagon-like peptide-1. It's a hormone your body naturally produces in response to eating. GLP-1 does several things: it signals your pancreas to release insulin, slows gastric emptying (how quickly food leaves your stomach), and communicates with your brain to reduce appetite.

GLP-1 receptor agonists are medications that mimic this hormone, but at higher and more sustained levels than your body produces on its own. The result is reduced hunger, earlier satiety (feeling full sooner), and in many cases, a meaningful reduction in food noise — that constant background preoccupation with what to eat next.

The two major players right now are:

• Semaglutide (brand names: Wegovy for weight loss, Ozempic for diabetes)
• Tirzepatide (brand names: Zepbound for weight loss, Mounjaro for diabetes)

Both are administered as weekly subcutaneous injections — a small needle, typically in the abdomen or thigh, once per week.

How Much Weight Can You Expect to Lose?

Clinical trial data is encouraging. In the STEP trials, patients on semaglutide lost an average of 15-17% of their body weight over 68 weeks. Tirzepatide showed even more impressive results in the SURMOUNT trials, with average weight loss of 20-26% depending on dose.

For a 250-pound patient, that translates to roughly 37-65 pounds over about 16 months.

These are averages. Some patients lose more, some less. Individual response depends on dose, diet, exercise, metabolic factors, and adherence. But the consistency of these results across large clinical trials is what makes GLP-1 medications genuinely different from previous weight loss drugs.

Who Qualifies?

FDA-approved indications for weight loss GLP-1 medications generally require:

• BMI of 30 or higher (obesity), or
• BMI of 27 or higher with at least one weight-related health condition (type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, cardiovascular disease)

Your physician will also evaluate your medical history, current medications, and whether other approaches have been tried. GLP-1 medications aren't a first-line treatment for someone who hasn't attempted lifestyle modifications — but they're also not a last resort. They're a medical tool for a medical condition.

What to Expect When Starting

GLP-1 medications are started at a low dose and gradually increased over several weeks to months. This titration process helps minimize side effects and allows your body to adjust.

The first few weeks: Most patients notice reduced appetite within the first week or two. You may find that portion sizes naturally decrease and cravings diminish. Some patients describe it as "the volume being turned down" on hunger.

Common side effects: Nausea is the most frequently reported side effect, particularly during dose increases. Other GI effects include constipation, diarrhea, and occasionally vomiting. For most patients, these are mild and improve over time. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help.

Dose escalation: Your physician will increase your dose at scheduled intervals until you reach your target dose. If side effects are significant at a particular dose, you may stay at that level longer before increasing.

The Florida Landscape

Florida has some specific considerations for GLP-1 therapy:

Availability: Shortages have been a reality since 2022. While supply has improved, certain doses and formulations can still be intermittently unavailable. Your physician should have a plan for managing potential supply disruptions.

Insurance coverage: Coverage varies significantly by plan. Some commercial insurers cover Wegovy or Zepbound for weight loss. Medicare currently does not cover GLP-1 medications for weight loss (though legislation is pending). Medicaid coverage varies by state — Florida Medicaid has limited coverage for these medications.

Compounded alternatives: The shortage has created a market for compounded semaglutide and tirzepatide. These are produced by compounding pharmacies rather than the original manufacturers. While legal under current FDA shortage designations, quality and dosing consistency can vary. If you're considering a compounded option, work with a physician who understands the differences and can monitor your response.

Telehealth access: Florida law permits prescribing GLP-1 medications via telehealth after an appropriate medical evaluation. This means patients across the state — from Miami to Jacksonville to the Panhandle — can access physician-supervised weight loss programs without an in-person visit for every appointment. CORAL offers telehealth consultations specifically for weight management.

What GLP-1 Medications Don't Do

These medications are not magic. They reduce appetite and help with portion control, but they don't:

• Replace nutrition knowledge. You still need to eat well — adequate protein, vegetables, whole foods. Eating less doesn't automatically mean eating better.
• Build muscle. Weight lost on GLP-1 medications includes some lean mass. Resistance training and adequate protein intake are essential to preserve muscle.
• Work forever without maintenance. Current evidence shows that most patients regain weight if they stop the medication entirely. This is a chronic condition requiring ongoing management.
• Fix underlying metabolic issues alone. Thyroid disorders, insulin resistance, hormonal imbalances, sleep disorders, and medications that promote weight gain all need to be addressed alongside GLP-1 therapy.

How CORAL Approaches GLP-1 Therapy

At CORAL, weight management starts with a comprehensive evaluation — not a quick prescription. Dr. Tae Y. Kim, DO, reviews your medical history, current medications, lab work, and weight loss goals before determining whether a GLP-1 medication is appropriate.

If GLP-1 therapy is recommended, your treatment plan includes:

• Regular follow-ups to monitor progress and manage side effects
• Dose adjustments based on your individual response
• Guidance on nutrition, protein intake, and exercise
• Lab monitoring as needed
• Ongoing access to your physician via telehealth

Frequently Asked Questions

How quickly do GLP-1 injections work?

Most patients notice reduced appetite within the first one to two weeks. Meaningful weight loss typically becomes apparent within the first month, with the most significant results seen over 6-12 months as you reach and maintain your target dose.

Do I have to inject myself?

Yes, but the injection process is straightforward. GLP-1 medications come in prefilled pens with small needles. Most patients find the process much simpler than they expected. Your physician or care team will walk you through the technique.

Can I take GLP-1 medications if I have diabetes?

GLP-1 receptor agonists were originally developed for type 2 diabetes, so they can serve a dual purpose. However, if you're on other diabetes medications, your doses may need adjustment to avoid hypoglycemia. Your physician will coordinate this.

What happens if I stop taking the medication?

Research consistently shows that weight regain occurs in most patients who discontinue GLP-1 therapy entirely. This is because obesity is a chronic metabolic condition, not a temporary problem. Many patients benefit from long-term or indefinite use, though the dose may be adjusted over time.

Are GLP-1 medications safe long-term?

Semaglutide has been on the market since 2017 (for diabetes) and has extensive safety data. The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events in patients on semaglutide — meaning these medications may actually provide cardiovascular protection. Ongoing monitoring with your physician is still recommended.

---

If you're considering GLP-1 therapy for weight loss, CORAL offers physician-supervised weight management programs with telehealth convenience. [Start your consultation today](/start) to find out whether a GLP-1 medication is right for you.